10-Q: Logiq Inc. Reports Third Quarter 2024 Results, Revenue Impacted by Strategic Shift

Logiq Inc. reports a net loss of $197,349 for the third quarter of 2024, with no service revenue, reflecting the impact of strategic spin-offs and a focus on higher margin business.

Summary

• Logiq Inc. reported a net loss of $197,349 for the three months ended September 30, 2024, compared to a net loss of $3,934,443 for the same period in 2023.
• The company's service revenue was $0 for the third quarter of 2024, a significant decrease from $3,265,674 in the third quarter of 2023.
• For the nine months ended September 30, 2024, the net loss was $1,077,841, compared to a net loss of $19,948,158 for the same period in 2023.
• The company's service revenue for the nine months ended September 30, 2024 was $0, compared to $11,663,762 for the same period in 2023.
• The company completed the spin-offs of its AppLogiq and DataLogiq businesses, which significantly impacted revenue and expenses.
• Operating expenses decreased substantially due to the spin-offs, with general and administrative expenses at $197,349 for the quarter and $1,077,841 for the nine months ended September 30, 2024.
• The company issued 1,500,000 shares of common stock for stock-based compensation during the three months ended September 30, 2024.
• As of November 8, 2024, the company had 279,447,540 shares of common stock issued and outstanding.

Sentiment

Score: 4

Explanation: The document shows a mixed picture. While the company has reduced its losses and is diversifying into biotech, the lack of revenue, material weaknesses in internal controls, and the history of restatements are significant concerns. The strategic shift is a positive, but the execution and future outlook remain uncertain.

Positives

• The net loss significantly decreased for both the three and nine month periods ending September 30, 2024, compared to the same periods in 2023.
• Operating expenses, particularly general and administrative costs, were substantially reduced due to the spin-offs of AppLogiq and DataLogiq.
• The company is diversifying into the biotech sector with the planned acquisition of MedLab Essentials, LLC.
• The company has taken steps to address material weaknesses in internal controls by providing training to finance personnel.

Negatives

• The company reported zero service revenue for both the three and nine months ended September 30, 2024, due to the spin-offs of its AppLogiq and DataLogiq businesses.
• The company continues to operate at a loss, with a net loss of $197,349 for the quarter and $1,077,841 for the nine months ended September 30, 2024.
• The company's disclosure controls and procedures were deemed ineffective due to material weaknesses in internal control over financial reporting.
• The company has a history of restating financial statements due to material weaknesses in internal controls.

Risks

• The company's reliance on a single cloud-based hosting provider poses a risk to its operations.
• The company's internal control over financial reporting was deemed ineffective due to material weaknesses.
• The company's ability to raise additional capital is uncertain, which could impact its operations and expansion plans.
• The company's financial results have been significantly impacted by the spin-offs of its AppLogiq and DataLogiq businesses.
• The company has a history of losses and may not achieve profitability in the near future.

Future Outlook

The company expects an uncertain outlook in its service revenues due to the ongoing impact of the COVID-19 pandemic and is focusing on higher margin business. The acquisition of MedLab Essentials, LLC is expected to close no later than January 31, 2025.

Management Comments

• The company believes that SMBs can increase their sales, reach more customers, and promote their products and services using its affordable and cost-effective solutions.
• Given the recent decline in the stock market and specifically in the price of technology stocks, we felt that it was time to replicate the same strategy and evaluate a higher margin path again.

Industry Context

The company's strategic shift to focus on higher margin business and the spin-offs of its AppLogiq and DataLogiq businesses reflect a broader trend of companies streamlining operations and focusing on core competencies. The move into the biotech sector with the acquisition of MedLab Essentials, LLC is a significant diversification strategy.

Comparison to Industry Standards

• Logiq's revenue decline is significant compared to industry peers that have not undergone similar spin-offs. Companies like HubSpot and Salesforce, which operate in the SaaS space, have shown consistent revenue growth.
• The company's net loss, while improved year-over-year, is still a concern compared to profitable companies in the digital marketing and technology sectors.
• The material weaknesses in internal control are a significant deviation from industry best practices, where robust internal controls are expected, especially for public companies.
• The acquisition of MedLab Essentials, LLC is a unique move, as most digital marketing companies do not diversify into biotech. This makes direct comparison difficult.

Corporate Governance

Related Party Transactions

• The amount due from related party pertains to expenses paid on behalf of GoLogiq Inc. This amount is interest-free, unsecured and does not have fixed repayment terms.

Stakeholder Impact

• Shareholders have experienced significant dilution due to the issuance of new shares.
• Employees may be impacted by the restructuring and strategic shift of the company.
• Customers of the spun-off businesses may experience changes in service or support.
• Creditors may be concerned about the company's ongoing losses and uncertain financial outlook.

Next Steps

• The company plans to close the acquisition of MedLab Essentials, LLC by January 31, 2025.
• The company will continue to evaluate its capital expenditure needs and may seek additional financing if necessary.
• The company will continue to implement changes to its internal control over financial reporting to address the identified material weaknesses.

Key Dates

Keywords

Logiq, financial results, spin-off, net loss, revenue, operating expenses, internal control, MedLab Essentials, biotech, stock-based compensation